Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Marshall Wace LLP

Marshall Wace LLP lifted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 27.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,051,573 shares of the biopharmaceutical company's stock after buying an additional 229,561 shares during the period. Marshall Wace LLP owned approximately 1.14% of Ultragenyx Pharmaceutical worth $44,240,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. M&T Bank Corp boosted its position in Ultragenyx Pharmaceutical by 8.1% in the third quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company's stock valued at $388,000 after buying an additional 525 shares during the last quarter. Geode Capital Management LLC grew its holdings in Ultragenyx Pharmaceutical by 4.4% during the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock worth $87,296,000 after acquiring an additional 65,623 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in Ultragenyx Pharmaceutical during the third quarter valued at approximately $83,000. Principal Financial Group Inc. lifted its holdings in Ultragenyx Pharmaceutical by 740.0% in the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock valued at $4,802,000 after acquiring an additional 76,150 shares during the period. Finally, Nordea Investment Management AB boosted its position in Ultragenyx Pharmaceutical by 8.9% in the 4th quarter. Nordea Investment Management AB now owns 39,673 shares of the biopharmaceutical company's stock worth $1,658,000 after purchasing an additional 3,246 shares in the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on RARE. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler decreased their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. HC Wainwright reaffirmed a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Canaccord Genuity Group boosted their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Finally, Wedbush reaffirmed a "neutral" rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of "Moderate Buy" and a consensus target price of $92.79.

Ultragenyx Pharmaceutical Trading Up 2.6 %

NASDAQ:RARE traded up $0.95 during trading hours on Wednesday, hitting $36.86. The company's stock had a trading volume of 259,922 shares, compared to its average volume of 811,102. The stock has a market capitalization of $3.46 billion, a P/E ratio of -5.81 and a beta of 0.61. The stock has a fifty day moving average of $38.10 and a 200-day moving average of $43.93. Ultragenyx Pharmaceutical Inc. has a 52-week low of $29.59 and a 52-week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at $2,358,014.08. The trade was a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Theodore Alan Huizenga sold 967 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $40,710.70. Following the completion of the sale, the chief accounting officer now directly owns 50,265 shares in the company, valued at $2,116,156.50. This represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 124,643 shares of company stock valued at $5,256,268. Insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.